Cowen & Co. Reiterates Their Buy Rating on Acorda Therapeutics

By Jason Carr

Cowen & Co. analyst Phil Nadeau reiterated a Buy rating on Acorda Therapeutics (NASDAQ: ACOR) on November 15 and set a price target of $30. The company’s shares closed yesterday at $17.25.

According to, Nadeau is a 4-star analyst with an average return of 8.4% and a 50.0% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Catabasis Pharmaceuticals, and Voyager Therapeutics Inc.

Currently, the analyst consensus on Acorda Therapeutics is Hold and the average price target is $20.80, representing a 20.6% upside.

In a report issued on November 8, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $35 price target.

The company has a one-year high of $33 and a one-year low of $13.60. Currently, Acorda Therapeutics has an average volume of 938.4K.

Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ACOR in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Acorda Therapeutics, Inc. develops and markets therapeutic products for nervous system disorders. The company’s two main products are Ampyra and Zanaflex Capsules.